Viridian Therapeutics Inc. (VRDN)
VRDN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/0001590750-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VRDN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001590750 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $70.8M |
| Net income | -$342.6M |
| Operating income | -$363.4M |
| Net margin | -483.6% |
| Operating margin | -512.9% |
| Revenue growth | +23359.9% |
| Cash | $212.4M |
| Total assets | $899.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 47.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $172.9M cash; operating cash flow -$85.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 113,558,449 (2026-11-02); 95,442,008 a year earlier; 52,586,039 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-05-08 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $30.0M, sold $419K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $25.8M | -$101.2M | -$92.8M | $172.9M | $121.6M | $26.3M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $284K | -$127.1M | -$105.3M | $165.0M | $113.6M | $71.1M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $141K | -$104.9M | -$119.7M | $176.3M | $36.1M | $70.9M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $132K | -$120.4M | -$23.8M | $212.4M | $34.2M | $70.8M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $70.6M | -$34.6M | -$84.6M | $169.6M | $20.9M | $70.8M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $75K | -$100.7M | -$75.4M | $117.3M | $20.8M | $305K | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $72K | -$86.9M | -$92.7M | $116.2M | $20.7M | $302K | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $72K | -$79.7M | -$73.3M | $99.6M | $20.6M | $302K | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-08 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 821 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +8.4% |
| 1 month | +69.4% |
| 3 months | +40.4% |
| Year to date | -0.8% |
| 1 year | +8.4% |
| From 52-week high | -8.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VKTX | Viking Therapeutics Inc. | $26.80 | -8.28% | $3.4B |
| ARQT | Arcutis Biotherapeutics Inc. | $27.15 | -3.93% | $3.4B |
| IRON | Disc Medicine Inc. | $76.59 | -4.26% | $3.5B |
| ELVN | Enliven Therapeutics Inc. | $47.62 | -2.42% | $3.5B |
| PBLS | Parabilis Medicines Inc. | $28.45 | +0.07% | $3.5B |
| ACAD | ACADIA Pharmaceuticals Inc. | $18.67 | -0.43% | $3.2B |
| AMLX | Amylyx Pharmaceuticals Inc. | $27.80 | -8.22% | $3.6B |
| ABCL | AbCellera Biologics Inc. Common Shares | $11.12 | -3.22% | $3.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier